Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14374937 | 0.86 | — | — | |
| SCHEMBL24115804 | 0.86 | — | — | |
| SCHEMBL9376104 | 0.84 | EPHX1 (0.50) | EPHX1NOS3NOS1NOS2 | |
| SCHEMBL15107729 | 0.82 | — | — | |
| SCHEMBL20220488 | 0.78 | — | — | |
| SCHEMBL31041748 | 0.77 | CA1 (0.47) | EPHX1CA1CA2CA4 | |
| SCHEMBL16827221 | 0.77 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL12060473 | 0.76 | — | — | |
| SCHEMBL2051111 | 0.76 | — | — | |
| SCHEMBL14050270 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-9688670-B2 | Benzimidazole compounds and medical uses thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | KCNA7, SCN1A, KCNA1 | EPHX1 2940/4885NOS3 1023/4885NOS1 1202/4885 |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SCN1B, SCN1A, KCNA7 | EPHX1 2695/4885NOS3 1012/4885NOS1 981/4885 |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | KCNA7, SCN1A, KCNA1 | EPHX1 2940/4885NOS3 1023/4885NOS1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.